RECRUITING

Effects of MRSA Bactericidal Gel To Promote Healing and Eliminate MRSA in cSSTI Vancogel(TM)

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Based on personal experience and the literature it is reasonable expectation that Vancomycin is a viable treatment in a direct contact form to eliminate MRSA from open wounds in order to heal the wounds by conventional means. The key question in my research has been to measure the effectiveness of my Vancomycin Gel by culturing the wound, applying the Gel in a controlled manner and then culturing the wound after one week. The end point to achieve in the process, is a clinical response of accelerated healing and negative culture report. Another question to solve is the duration of potency and stability of the Vancomycin gel over time.

Official Title

Topical MRSA Bactericidal Gel to Eliminate MRSA and Promote Accelerated Healing of cSSTI of Open Wounds

Quick Facts

Study Start:2011-07-15
Study Completion:2024-12-15
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT00945152

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * MRSA infected open wounds
  2. * Acute and chronic wounds
  3. * Type of wounds: venous stasis,diabetic, pressure, post surgical, post traumatic, and spontaneous
  4. * Infection criteria: Include a positive culture for MRSA
  5. * Location of ulcers: any place on the body
  6. * Diagnosis of MRSA: Based on tissue cultures of MRSA
  7. * Willing and reliable patients
  8. * Study to include only one ulceration no more than 50 square centimeters
  9. * The study to include stages two and three ulcerations
  1. * Non-compliant patients
  2. * Patient must accept all issues in consent form
  3. * Non compliance to include failed appointments
  4. * Wounds greater than 50sq. cm
  5. * No wounds deeper than soft tissue
  6. * Ischemic or vascular disease, dermatitis, immune deficiency,or psoriasis
  7. * Allergy to Vancomycin
  8. * Post irradiation ulceration
  9. * Bleeding disorders
  10. * Skin allergies to adhesives and tape
  11. * Ulcers related to cancers
  12. * Multiple wounds
  13. * Stage 4 ulcerations
  14. * Patients in any other trial
  15. * Patients with any other conditions which, in the opinion of the investigator/doctor, would preclude participation in the study.

Contacts and Locations

Study Contact

Robert S Berman, MD
CONTACT
561-628-0040
bermanmd@comcast.net

Principal Investigator

Robert S Berman, MD
PRINCIPAL_INVESTIGATOR

Study Locations (Sites)

Robert S Berman MD /661 Maplewood Drive #21
Jupiter, Florida, 33458
United States

Collaborators and Investigators

Sponsor: Robert S Berman MD

  • Robert S Berman, MD, PRINCIPAL_INVESTIGATOR

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2011-07-15
Study Completion Date2024-12-15

Study Record Updates

Study Start Date2011-07-15
Study Completion Date2024-12-15

Terms related to this study

Keywords Provided by Researchers

  • Elimination of MRSA in open wounds
  • MRSA infected open wounds

Additional Relevant MeSH Terms

  • Bacterial Infections
  • Wounds